There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Fresenius Medical Care AG & Co. KGaA (GB:0H9X – Research Report), Omega Therapeutics (OMGA – Research Report) and Alpine Immune Sciences (ALPN – Research Report) with bullish sentiments.
Fresenius Medical Care AG & Co. KGaA (GB:0H9X)
Goldman Sachs analyst Richard Felton maintained a Buy rating on Fresenius Medical Care AG & Co. KGaA yesterday and set a price target of EUR49.00. The company’s shares closed yesterday at EUR36.92.
According to TipRanks.com, Felton is ranked #2014 out of 8824 analysts.
The word on The Street in general, suggests a Hold analyst consensus rating for Fresenius Medical Care AG & Co. KGaA with an EUR36.85 average price target, a -2.6% downside from current levels. In a report released yesterday, Berenberg Bank also maintained a Buy rating on the stock with a EUR47.00 price target.
See today’s best-performing stocks on TipRanks >>
Omega Therapeutics (OMGA)
Chardan Capital analyst Keay Nakae maintained a Buy rating on Omega Therapeutics on March 31 and set a price target of $7.00. The company’s shares closed last Tuesday at $2.16, close to its 52-week low of $1.30.
According to TipRanks.com, Nakae is a 3-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Omega Therapeutics with a $9.33 average price target, representing a 297.0% upside. In a report issued on April 3, Piper Sandler also reiterated a Buy rating on the stock with a $9.00 price target.
Alpine Immune Sciences (ALPN)
In a report issued on April 11, Tara Bancroft from TD Cowen maintained a Buy rating on Alpine Immune Sciences. The company’s shares closed last Tuesday at $64.64, close to its 52-week high of $64.72.
According to TipRanks.com, Bancroft is a 5-star analyst with an average return of
The word on The Street in general, suggests a Hold analyst consensus rating for Alpine Immune Sciences with a $61.50 average price target, implying a -4.8% downside from current levels. In a report issued on April 9, Guggenheim also initiated coverage with a Buy rating on the stock with a $55.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on GB:0H9X:
- Fresenius Medical Care starts the year with strong earnings growth
- Fresenius Medical rises 10.2%
- Fresenius Medical rises 9.5%
- Fresenius Medical Care AG & Co. KGaA (0H9X) Reveals Q2 Dividend: Here’s the Essential Information
- Fresenius Medical price target raised to EUR 34 from EUR 33 at Morgan Stanley
